JAMES ENLOU TCHENG, MD
Osteopathic Medicine at Duke Medicine Cir, Durham, NC
License number
North Carolina 32586
Category
Osteopathic Medicine
Type
Cardiovascular Disease
Address
Address
40 Duke Medicine Cir, Durham, NC 27710
Phone
(919) 684-8111
Personal information
See more information about JAMES ENLOU TCHENG at radaris.comName
Address
Phone
4110 Thetford Rd, Durham, NC 27707
3416 Balfour, Durham, NC 27713
4108 Thetford Rd, Durham, NC 27707
4110 Thetford Rd, Durham, NC 27707
Professional information
Dr. James E Tcheng, Durham NC - MD (Doctor of Medicine)
Specialties:
Cardiology, Interventional Cardiology
Address:
40 Duke Medicine Cir, Durham 27710
(919) 684-8111 (Phone)
DUKE MEDICAL CENTER
2424 Erwin Rd SUITE 403, Durham 27705
(800) 266-3853 (Phone)
DUKE MEDICINE
4101 N Roxboro St, Durham 27704
(800) 266-3853 (Phone), (919) 681-7292 (Fax)
(919) 684-8111 (Phone)
DUKE MEDICAL CENTER
2424 Erwin Rd SUITE 403, Durham 27705
(800) 266-3853 (Phone)
DUKE MEDICINE
4101 N Roxboro St, Durham 27704
(800) 266-3853 (Phone), (919) 681-7292 (Fax)
Certifications:
Cardiovascular Disease, 1989, Internal Medicine, 1985, Interventional Cardiology, 2003
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Johns Hopkins University / School of Medicine
Graduated: 1982
Barnes-Jewish Hospital
Duke University Sch Med
Johns Hopkins University / School of Medicine
Graduated: 1982
Barnes-Jewish Hospital
Duke University Sch Med
James Tcheng, Durham NC
Specialties:
Internal Medicine, Cardiovascular Disease, Cardiology, Interventional Cardiology
Work:
Durham Va Medical Center
508 Fulton St, Durham, NC 27705 Duke University
2424 Erwin Rd, Durham, NC 27705 Duke Cardiology Of Lumberton
2936 N Elm St, Lumberton, NC 28358 Duke Cardiology Of Lumberton
403 W 27Th St, Lumberton, NC 28358 Private Diagnostic Clinic
1000 Trent Dr, Durham, NC 27710
508 Fulton St, Durham, NC 27705 Duke University
2424 Erwin Rd, Durham, NC 27705 Duke Cardiology Of Lumberton
2936 N Elm St, Lumberton, NC 28358 Duke Cardiology Of Lumberton
403 W 27Th St, Lumberton, NC 28358 Private Diagnostic Clinic
1000 Trent Dr, Durham, NC 27710
Education:
Johns Hopkins University (1982)
Combination Therapy For Inhibition Of Platelet Aggregation
US Patent:
2007008, Apr 12, 2007
Filed:
Sep 5, 2006
Appl. No.:
11/515596
Inventors:
R. Porter - Franklin TN, US
Kristen Flaharty - Fort Myers FL, US
James Tcheng - Durham NC, US
John Ferkany - Brighton MA, US
Kristen Flaharty - Fort Myers FL, US
James Tcheng - Durham NC, US
John Ferkany - Brighton MA, US
International Classification:
A61K 38/12, A61K 38/06, A61K 38/05, A61K 31/727, A61K 31/5513, A61K 31/5377, A61K 31/445
US Classification:
514009000, 514018000, 514317000, 514221000, 514326000, 514232500, 514056000
Abstract:
The invention features methods for preventing platelet activation and aggregation and for treating individuals suffering from conditions or undergoing procedures that may result in unwanted platelet aggregation. The methods are based on the intravenous, subcutaneous, or transdermal administration of a platelet activation or aggregation inhibitor, e.g., xemilofiban, followed by oral administration of the same or a different platelet activation or aggregation inhibitor. The treatment may commence prior to a medical or surgical procedure or after the outbreak of an adverse medical condition, either of which results in the activation of platelets that may lead to thrombus formation, and may continue thereafter.
Combination Therapy For Inhibition Of Platelet Aggregation
US Patent:
2010004, Feb 18, 2010
Filed:
Aug 12, 2009
Appl. No.:
12/540062
Inventors:
R. Stephen PORTER - Franklin TN, US
Kristen K. Flaharty - Fort Myers FL, US
James E. Tcheng - Durham NC, US
John W. Ferkany - Brighton MA, US
Kristen K. Flaharty - Fort Myers FL, US
James E. Tcheng - Durham NC, US
John W. Ferkany - Brighton MA, US
International Classification:
A61K 38/16, A61K 31/727
US Classification:
514 8, 514 56
Abstract:
The invention features methods for preventing platelet activation and aggregation and for treating individuals suffering from conditions or undergoing procedures that may result in unwanted platelet aggregation. The methods are based on the intravenous, subcutaneous, or transdermal administration of a platelet activation or aggregation inhibitor, e.g., xemilofiban, followed by oral administration of the same or a different platelet activation or aggregation inhibitor. The treatment may commence prior to a medical or surgical procedure or after the outbreak of an adverse medical condition, either of which results in the activation of platelets that may lead to thrombus formation, and may continue thereafter.